Simple score to predict risk of hepatocellular carcinoma in chronic hepatitis C patients with advanced fibrosis after pegylated interferon and ribavirin therapy

References

• AlterMJEpidemiology of hepatitis C virus infectionWorld J Gastroenterol200713172436244117552026
   PubMed Web of Science ®Google Scholar
• TsukumaHHiyamaTTanakaSRisk factors for hepatocellular carcinoma among patients with chronic liver diseaseN Engl J Med199332825179718017684822
   PubMed Web of Science ®Google Scholar
• HuCCLinCLKuoYLEfficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis CAliment Pharmacol Ther2013371819023121150
   PubMed Web of Science ®Google Scholar
• FassioEHepatitis C and hepatocellular carcinomaAnn Hepatol20109Suppl11912220714008
   PubMed Web of Science ®Google Scholar
• PerzJFArmstrongGLFarringtonLAHutinYJBellBPThe contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwideJ Hepatol200645452953816879891
   PubMed Web of Science ®Google Scholar
• ColomboMde FranchisRDel NinnoEHepatocellular carcinoma in Italian patients with cirrhosisN Engl J Med1991325106756801651452
   PubMed Web of Science ®Google Scholar
• FattovichGGiustinaGDegosFMorbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patientsGastroenterology199711224634729024300
   PubMed Web of Science ®Google Scholar
• BrunoSStroffoliniTColomboMSustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective studyHepatology200745357958717326216
   PubMed Web of Science ®Google Scholar
• ShiratoriYItoYYokosukaOAntiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survivalAnn Intern Med2005142210511415657158
   PubMed Web of Science ®Google Scholar
• HungCHLeeCMLuSNLong-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosisJ Viral Hepat200613640941416842444
   PubMed Web of Science ®Google Scholar
• CardosoACMoucariRFigueiredo-MendesCImpact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosisJ Hepatol201052565265720346533
   PubMed Web of Science ®Google Scholar
• RutterKStattermayerAFBeinhardtSSuccessful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis CAliment Pharmacol Ther201541652153125616017
   PubMed Web of Science ®Google Scholar
• HsuCSHuangCJKaoJHInterferon-based therapy decreases risks of hepatocellular carcinoma and complications of cirrhosis in chronic hepatitis C patientsPLoS One201387e7045823894660
   PubMed Web of Science ®Google Scholar
• StraderDBWrightTThomasDLSeeffLBAmerican Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis CHepatology20043941147117115057920
   PubMed Web of Science ®Google Scholar
• WrightTLTreatment of patients with hepatitis C and cirrhosisHepatology2002365 Suppl 1S185S19412407593
   PubMed Web of Science ®Google Scholar
• IkedaKSaitohSKoidaIA multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosisHepatology199318147537686879
   PubMed Web of Science ®Google Scholar
• BrunoSCrosignaniAMaisonneuvePRossiSSiliniEMondelliMUHepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort studyHepatology20074651350135617680653
   PubMed Web of Science ®Google Scholar
• AlemanSRahbinNWeilandOA risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosisClin Infect Dis201357223023623616492
   PubMed Web of Science ®Google Scholar
• Fernandez-RodriguezCMAlonsoSMartinezSMPeginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting responseAm J Gastroenterol20101051021642172 quiz 217320700116
   PubMed Web of Science ®Google Scholar
• McHutchisonJGGordonSCSchiffERInterferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy GroupN Engl J Med199833921148514929819446
   PubMed Web of Science ®Google Scholar
• FriedMWShiffmanMLReddyKRPeginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionN Engl J Med20023471397598212324553
   PubMed Web of Science ®Google Scholar
• MannsMPMcHutchisonJGGordonSCPeginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialLancet2001358928695896511583749
   PubMed Web of Science ®Google Scholar
• Expert Committee on the Diagnosis and Classification of Diabetes MellitusReport of the Expert Committee on the Diagnosis and Classification of Diabetes MellitusDiabetes Care1997207118311979203460
   PubMed Web of Science ®Google Scholar
• BruixJShermanMPractice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinomaHepatology20054251208123616250051
   PubMed Web of Science ®Google Scholar
• HuCCLinCLChangLCInterleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control studyBMC Infect Dis20151515625888020
   PubMed Web of Science ®Google Scholar
• NagaokiYAikataHNakanoNDevelopment of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort studyJ Gastroenterol Hepatol20163151009101526584407
   PubMed Web of Science ®Google Scholar
• ContiFBuonfiglioliFScuteriAEarly occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antiviralsJ Hepatol201665472773327349488
   PubMed Web of Science ®Google Scholar
• HuCCWengCHLinCLNew score to predict risk of hepatocellular carcinoma in chronic hepatitis C patients after pegylated interferon and ribavirin therapyOncotargetIn press2017
   Google Scholar
• PaulSBGulatiMSSreenivasVEvaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoproteinOncology200772Suppl 111712318087192
   PubMed Web of Science ®Google Scholar
• TorzilliGMinagawaMTakayamaTInoueKHuiAMKubotaKOhtomoKMakuuchiMAccurate preoperative evaluation of liver mass lesions without fine-needle biopsyHepatology19993088989310498639
   PubMed Web of Science ®Google Scholar
• HuKQKyuloNLLimNElhazinBHillebrandDJBockTClinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinomaAm J Gastroenterol200499586086515128351
   PubMed Web of Science ®Google Scholar
• BayatiNSilvermanALGordonSCSerum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis CAm J Gastroenterol19989312245224569860408
   PubMed Web of Science ®Google Scholar
• ChuCWHwangSJLuoJCClinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis CJ Clin Gastroenterol200132324024411246354
   PubMed Web of Science ®Google Scholar
• Di BisceglieAMSterlingRKChungRTSerum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C TrialJ Hepatol200543343444116136646
   PubMed Web of Science ®Google Scholar
• Romero-GomezMDel Mar ViloriaMAndradeRJInsulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patientsGastroenterology2005128363664115765399
   PubMed Web of Science ®Google Scholar
• KonishiIHoriikeNHiasaYDiabetes mellitus reduces the therapeutic effectiveness of interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis CHepatol Res200737533133617441805
   PubMed Web of Science ®Google Scholar
• KawamuraYAraseYIkedaKDiabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patientsAm J Med201012310951956e95120920698
   PubMed Web of Science ®Google Scholar
• HungCHLeeCMWangJHImpact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapyInt J Cancer2011128102344235220669224
   PubMed Web of Science ®Google Scholar
• DonadonVBalbiMMasMDCasarinPZanetteGMetformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver diseaseLiver Int20103075075820331505
   PubMed Web of Science ®Google Scholar
• LaiSWChenPCLiaoKFMuoCHLinCCSungFCRisk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort studyAm J Gastroenterol2012107465222085817
   PubMed Web of Science ®Google Scholar
• ChangKCWuYYHungCHClinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapyBr J Cancer201310992481248824084770
   PubMed Web of Science ®Google Scholar
• TengWHsiehYCLuiKWEradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolizationJ Viral Hepat201724121160116728643457
   PubMed Web of Science ®Google Scholar
• ChangKCHungCHLuSNA novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapyJ Antimicrob Chemother201267112766277222899800
   PubMed Web of Science ®Google Scholar